Human Influenza Clinical Trial
Official title:
Prevention of Secondary Transmission of Human Influenza by Promoting Handwashing With Soap: The Bangladesh Interruption of Secondary Transmission of Influenza Study (BISTIS)
The next influenza pandemic is expected to spread rapidly in resource-poor settings.
Influenza viruses spread from human-to-human via large respiratory droplets. Transmission
via large-particle respiratory droplets is believed to be mediated by close contact between
infected and susceptible persons or contact with droplet-contaminated fomites. Close contact
between infected and susceptible persons may consist of skin-to-skin contact (e.g., via
hands) or inhalation of respiratory droplets (e.g., due to talking, coughing, or sneezing by
the infected person). Airborne transmission, which is expected to result in transmission
over long distances (>1 meter) and which would be mediated by ventilation, is believed to be
uncommon. Therefore, the greatest risk of transmission from personal contact comes from
those people who are closest to an index case, such as contacts living in the same
household. There are, to date, no published estimates of the secondary attack ratio of
influenza among household contacts of index case-patients in low-income countries. Moreover,
the investigators do not have data on the risk factors for secondary transmission of
influenza from index case-patients to their household contacts. There is some data for the
benefits of promoting handwashing with soap on the risk of all-cause acute respiratory
illness among children < 15 years old in a resource-poor setting in Pakistan. But, the
investigators do not have evidence that promoting handwashing with soap will acutely reduce
the risk of secondary transmission. Therefore, the investigators propose to conduct a study
in rural Bangladesh to assess the following:
- The secondary attack ratio of influenza among household contacts of an index
case-patient with influenza
- The risk factors for secondary transmission of influenza from an index case-patient to
household contacts
- The impact of promoting handwashing with soap on the risk of secondary transmission of
influenza from an index case-patient to household contacts
- The impact of handwashing promotion on handwashing behavior six months after
intervention
- The impact of handwashing promotion on the prevalence of respiratory infections,
diarrhea and influenza
Status | Completed |
Enrollment | 6600 |
Est. completion date | December 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Persons = 5 years old: Influenza-like illness (ILI), defined as history of fever and either cough or sore throat with fever onset within the previous 24 hours - Persons < 5 years old: any child with acute fever with onset within the previous 24 hours - Return to home within 24 hours of presentation to Upazilla Health Complex, Jahurul Islam Medical College Hospital or the local pharmacies; i.e., the index case cannot be admitted for treatment. If admitted, the patient would not be eligible. - No fever in any bari resident during the 7 days preceding the patient's presentation to hospital (see definition below) - At least two persons (in addition to the index case-patient) who intend to reside in the bari during the subsequent 20 days - Residence within 30 minutes travel time (one-way) from the Upazilla Health Complex or Jahurul Islam Medical College Hospital or the local pharmacy. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Bangladesh | Pavani K. Ram | Kishoreganj |
Lead Sponsor | Collaborator |
---|---|
International Centre for Diarrhoeal Disease Research, Bangladesh | State University of New York at Buffalo |
Bangladesh,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To test the efficacy of a handwashing promotion intervention for prevention of intrahousehold transmission of influenza virus in a rural setting in Bangladesh | 17 months | Yes | |
Secondary | To measure the secondary attack ratio of influenza among household contacts of influenza-infected persons in a rural setting in Bangladesh influenza-infected persons in a rural setting in Bangladesh | 17 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01690637 -
Panama and El Salvador Children's Oseltamivir Study
|
Phase 4 | |
Completed |
NCT03572491 -
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
|
Phase 3 | |
Recruiting |
NCT04487041 -
Tfh Dysfunction in HIV and Aging
|
Phase 4 | |
Completed |
NCT02387294 -
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
|
Phase 3 | |
Completed |
NCT02600585 -
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
|
N/A | |
Completed |
NCT02398097 -
Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects
|
Phase 4 | |
Completed |
NCT01511744 -
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
|
Phase 4 | |
Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
Completed |
NCT01677702 -
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
|
N/A | |
Active, not recruiting |
NCT01096225 -
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
|
N/A | |
Completed |
NCT01879540 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
|
Phase 2 | |
Completed |
NCT01879553 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT01651104 -
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
|
Phase 2 | |
Completed |
NCT01636102 -
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT03448705 -
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
|
Phase 1 | |
Completed |
NCT02478905 -
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
|
N/A | |
Recruiting |
NCT04431050 -
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
|
||
Completed |
NCT01568788 -
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
|
N/A | |
Completed |
NCT05155319 -
Universal Influenza A Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT01885117 -
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
|
Phase 3 |